Physician profile
Mark L Mankins
NPI 1952416158
$755.95
in general payments reported to CMS, 2019-2025
17 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2021: $46.33 · 2022: $129 · 2023: $114 · 2024: $40.70 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.47 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.43 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $185.82 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $91.32 | 2022-2025 | |
| Lundbeck LLC | $56.95 | 2025 | Vyepti |
| Mylan Specialty L.P. | $30.14 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.83 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $22.61 | 2023 | Nuedexta |
| Vifor Pharma, INC. | $20.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.75 | 2019 | |
| Axsome Therapeutics, INC. | $18.39 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $17.16 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.58 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.53 | 2019 | |
| Mdd US Operations, LLC | $12.27 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $12.20 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mankins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.